|Bid||75.00 x 900|
|Ask||100.00 x 2900|
|Day's Range||89.77 - 94.99|
|52 Week Range||23.81 - 96.54|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||50.04|
|Earnings Date||Feb 24, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||113.00|
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of a month-long virtual storytelling experience to elevate the diverse voices and faces of the rare disease community and benefit Make-A-Wish Mid-Atlantic and Make-A-Wish Canada. The #RAREis photobooth adds to a global commitment to helping grant the wishes of children with life-threatening rare diseases and provide moments of joy during a challenging time.
For any credit ratings referenced in this publication, please see the ratings tab on the issuer/entity page on www.moodys.com for the most updated credit rating action information and rating history. All rights reserved.CREDIT RATINGS ISSUED BY MOODY'S CREDIT RATINGS AFFILIATES ARE THEIR CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES, AND MATERIALS, PRODUCTS, SERVICES AND INFORMATION PUBLISHED BY MOODY’S (COLLECTIVELY, “PUBLICATIONS”) MAY INCLUDE SUCH CURRENT OPINIONS.
Supernus Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before.